Peri–CAR-T practice patterns and survival predictors for all CAR-T patients and post–CAR-T failure in aggressive B-NHL

Most patients receiving chimeric antigen receptor T-cell therapy (CAR-T) for aggressive B-cell non-Hodgkin lymphoma (B-NHL) do not experience a durable remission. Several novel agents are approved to treat relapsed, refractory aggressive B-NHL; however, it remains unclear how to sequence these thera...

Descripción completa

Detalles Bibliográficos
Autores principales: Zurko, Joanna, Nizamuddin, Imran, Epperla, Narendranath, David, Kevin, Cohen, Jonathon B., Moyo, Tamara K., Ollila, Thomas, Hess, Brian, Roy, Ishan, Ferdman, Robert, Liu, Jieqi, Chowdhury, Sayan Mullick, Romancik, Jason, Bhansali, Rahul S., Harris, Elyse I., Sorrell, Mckenzie, Masel, Rebecca, Kittai, Adam S., Denlinger, Nathan, Sigmund, Audrey M., Fitzgerald, Lindsey, Galvez, Carlos, Ma, Shuo, Winter, Jane, Pro, Barbara, Gordon, Leo I., Danilov, Alexey, Stephens, Deborah, Shah, Nirav N., Kenkre, Vaishalee, Barta, Stefan K., Torka, Pallawi, Shouse, Geoffrey, Karmali, Reem
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2022
Materias:
Clinical Trials and Observations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10333741/
https://www.ncbi.nlm.nih.gov/pubmed/36094847
http://dx.doi.org/10.1182/bloodadvances.2022008240

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10333741/
https://www.ncbi.nlm.nih.gov/pubmed/36094847
http://dx.doi.org/10.1182/bloodadvances.2022008240

Ejemplares similares